India is currently facing a critical shortage of Cisplatin and Carboplatin, two widely used chemotherapy drugs essential for cancer treatment. This shortage has emerged over the past two weeks, alarming oncologists who warn that it disrupts treatment schedules for thousands of cancer patients. The primary cause of the shortage is a significant increase in raw material costs, particularly platinum, driven by geopolitical tensions and rising demand in the semiconductor industry. Simultaneously, government price controls set by the National Pharmaceutical Pricing Authority (NPPA) have prevented manufacturers from adjusting prices to reflect these increased costs, leading to unsustainable profit margins. As a result, many pharmaceutical companies have halted production, exacerbating the crisis. Medical professionals are expressing their concerns on social media and calling for immediate government action to address the situation. They highlight the ethical dilemmas faced in rationing these life-saving drugs and the desperate measures patients are resorting to, including seeking alternatives that are often less effective and more expensive.